Last updated date
ABOUT THIS STUDY
The purpose of this study is to demonstrate the usability of the system.
Study Location
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
Erectile Dysfunction
Sex
Male
Age
40-70 years
Inclusion Criteria
Show details
Age 40 to 70
Exclusion Criteria
Show details
Prior syringe skills
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Erectile DysfunctionEffect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
NCT00313898
- Haifa,
Male
35 Years+
years
MULTIPLE SITES
Erectile DysfunctionA Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate
NCT00904748
- Braganca Paulista, SP
Male
18 Years+
years
MULTIPLE SITES
Erectile DysfunctionA Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects
NCT00866463
- New Haven, Connecticut
Male
18 Years+
years
MULTIPLE SITES
Erectile DysfunctionA Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Sildenafil And Tadalafil
NCT00644956
- Oslo,
- Leeds,
Male
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Caverject User Study | |||
Official Title ICMJE | Representative Users Study Of Operating Characteristics Of The Caverject Delivery System. | |||
Brief Summary | The purpose of this study is to demonstrate the usability of the system. | |||
Detailed Description | demonstrate usability | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) | |||
Condition ICMJE | Erectile Dysfunction | |||
Intervention ICMJE | Other: delivery system
syringe | |||
Study Arms ICMJE | Experimental: Caverject Impulse
representative users Intervention: Other: delivery system | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 48 | |||
Original Estimated Enrollment ICMJE | 50 | |||
Actual Study Completion Date ICMJE | February 2011 | |||
Actual Primary Completion Date | February 2011 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria: Age 40 to 70 Exclusion Criteria: Prior syringe skills | |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 40 Years to 70 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | Yes | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT01008605 | |||
Other Study ID Numbers ICMJE | A6711035 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | April 2012 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |